X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (827) 827
Newsletter (116) 116
Publication (58) 58
Book Review (7) 7
Newspaper Article (2) 2
Book Chapter (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
systemic lupus erythematosus (832) 832
lupus (610) 610
index medicus (549) 549
rheumatology (508) 508
humans (481) 481
female (405) 405
male (342) 342
adult (329) 329
middle aged (262) 262
severity of illness index (173) 173
young adult (170) 170
disease-activity (157) 157
nephritis (157) 157
adolescent (152) 152
classification (149) 149
patients (147) 147
immunology (142) 142
research (133) 133
lupus erythematosus, systemic - complications (127) 127
risk factors (127) 127
lupus erythematosus, systemic - drug therapy (123) 123
medical research (123) 123
lupus erythematosus, systemic - immunology (116) 116
medicine, experimental (116) 116
autoimmune diseases (115) 115
arthritis (112) 112
lupus erythematosus, systemic - blood (108) 108
disease (107) 107
lupus nephritis (101) 101
prevalence (100) 100
analysis (98) 98
autoantibodies (98) 98
index (98) 98
care and treatment (97) 97
sle (97) 97
lupus erythematosus, systemic - diagnosis (94) 94
disease activity (93) 93
lupus erythematosus, systemic - physiopathology (91) 91
mortality (88) 88
medicine & public health (87) 87
skin and connective tissue diseases (86) 86
aged (84) 84
child (79) 79
antibodies (78) 78
health risk assessment (77) 77
diagnosis (74) 74
inflammation (73) 73
clinical medicine (69) 69
retrospective studies (68) 68
case-control studies (67) 67
revised criteria (67) 67
risk-factors (66) 66
systemic-lupus-erythematosus (64) 64
erythematosus (63) 63
cross-sectional studies (62) 62
lupus erythematosus, systemic - epidemiology (62) 62
biomarkers (61) 61
disease progression (61) 61
health aspects (61) 61
rheumatoid-arthritis (61) 61
research article (58) 58
autoimmunity (57) 57
lupus erythematosus, systemic - pathology (57) 57
criteria (56) 56
prospective studies (56) 56
cytokines (55) 55
damage (54) 54
immunoglobulins (54) 54
medicine (54) 54
clinical trials (53) 53
medical and health sciences (51) 51
medicin och hälsovetenskap (51) 51
quality of life (51) 51
reports (51) 51
treatment outcome (51) 51
children (49) 49
cohort studies (49) 49
prognosis (49) 49
chronic conditions (48) 48
disease-activity index (47) 47
klinisk medicin (47) 47
association (46) 46
enzyme-linked immunosorbent assay (46) 46
corticosteroids (45) 45
validation (45) 45
follow-up studies (44) 44
reumatologi och inflammation (44) 44
rheumatology and autoimmunity (44) 44
laboratories (43) 43
rheumatoid arthritis (43) 43
studies (43) 43
biomarkers - blood (42) 42
immunosuppressive agents - therapeutic use (42) 42
cohort (41) 41
pathogenesis (41) 41
remission (41) 41
women (41) 41
lymphocytes (40) 40
time factors (40) 40
development and progression (39) 39
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Rheumatology, ISSN 0315-162X, 08/2015, Volume 42, Issue 8, pp. 1401 - 1405
Journal Article
Lupus, ISSN 0961-2033, 10/2012, Volume 21, Issue 12, pp. 1305 - 1311
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2018, Volume 77, Issue Suppl 2, p. 705
BackgroundUstekinumab (UST), a monoclonal antibody that targets shared p40 subunit of cytokines IL-12 and IL-23, is being investigated in pts w/active systemic... 
Lupus | Systemic lupus erythematosus | Research & development--R&D | Response rates | Clinical trials | Monoclonal antibodies | Interleukin 23 | Interleukin 12
Journal Article
The Journal of Rheumatology, ISSN 0315-162X, 02/2002, Volume 29, Issue 2, pp. 288 - 291
Journal Article
Journal Article
Experimental and Therapeutic Medicine, ISSN 1792-0981, 05/2017, Volume 13, Issue 5, pp. 2577 - 2583
Measurement of disease activity in patients with systemic lupus erythematosus (SLE) is important for monitoring disease progression and evaluating the... 
Calreticulin | SLEDAI-2K score | Disease activity | Systemic lupus erythematosus | RHEUMATOID-ARTHRITIS | AUTOANTIBODIES | ANTIBODIES | MEDICINE, RESEARCH & EXPERIMENTAL | VITAMIN-D | MANAGEMENT | CHAPERONE | SLE | systemic lupus erythematosus | disease activity | calreticulin | HEALTH | ACTIVITY INDEX
Journal Article
Arthritis Care & Research, ISSN 2151-464X, 11/2015, Volume 67, Issue 11, pp. 1609 - 1614
Journal Article
Lancet (London, England), ISSN 0140-6736, 10/2018, Volume 392, Issue 10155, pp. 1330 - 1339
Background: Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic... 
CELLS | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA | BELIMUMAB | DISEASE | NEPHRITIS | INDEX | SLE | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Humans | Middle Aged | Ustekinumab - pharmacology | Antibodies, Monoclonal - adverse effects | Male | Interleukin-12 - metabolism | Interleukin-23 - immunology | Ustekinumab - adverse effects | Interleukin-23 - metabolism | Antibodies, Monoclonal - administration & dosage | Interleukin-12 - immunology | Lupus Erythematosus, Systemic - drug therapy | Adult | Female | Infusions, Intravenous | Lupus Erythematosus, Systemic - physiopathology | Ustekinumab - administration & dosage | Lupus | Care and treatment | Systemic lupus erythematosus | Interleukins | Analysis | Therapy | Plasma | Nephritis | Intravenous administration | Disease | Pathogenesis | Interleukin | Medical services | Clinical trials | Interleukin 23 | Arthritis | Infections | Lupus nephritis | Risk factors | Infusion | Randomization | Motivation | Safety | Intravenous infusion | Drug dosages | Weighing | Immunoglobulins | Herpes zoster | Effectiveness | Cytokines | Psoriasis | Research & development--R&D | Medical treatment | Interleukin 12 | Inflammation | Patients | Chronic conditions | Crohn's Disease | Tuberculosis | Interactive systems | Biopsy | Response rates | Monoclonal antibodies | Adults | Skin | Autoimmune diseases
Journal Article